Why the Single-Use Bioprocessing Market is Skyrocketing

The global single-use bioprocessing market is expected to reach USD 20.8 billion by 2026 from USD 8.2 billion in 2021, at a CAGR of 20.5%

The global single-use bioprocessing market is experiencing explosive growth, projected to skyrocket from $8.2 billion in 2021 to $20.8 billion by 2026 at an impressive 20.5% compound annual growth rate (CAGR). This surge is fueled by the increasing demand for biopharmaceuticals, driven by an aging global population more susceptible to chronic conditions.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231651297

Single-use bioprocessing systems offer numerous advantages over traditional stainless-steel equipment, including greater energy efficiency, reduced water usage, smaller footprints, lower costs, quicker implementation, and diminished risk of cross-contamination. While concerns exist around extractables, leachables, and waste disposal, emerging markets in Asia like China and India present lucrative opportunities for this technology.

Major players like Sartorius, Danaher’s Cytiva, Thermo Fisher, and Merck are making massive investments to expand single-use bioprocessing capabilities and meet soaring demand for biologics and vaccines. Thermo Fisher alone invested over $475 million in 2020 to bolster its St. Louis facilities.

Sartorius Stedim Biotech held the leading position in the single-use bioprocessing market in 2020. Sartorius focuses on strengthening its position in the market by adopting organic and inorganic strategies such as product launches and expansions. During the past three years, Sartorius Stedim Biotech launched SUB systems such as BIOSTAT STR Generation 3 Single-Use Bioreactor, BIOSTAT RM TX Single-Use Bioreactor, and BIOSTAT STR. In 2019, Sartorius acquired Danaher’s Life Science portfolio, which is complementary to the portfolio of Sartorius’s laboratory and bioprocess business. In 2019, the company also expanded their operations in Puerto Rico.

Thermo Fisher Scientific is the second-largest player in the single-use bioprocessing market. Thermo Fisher Scientific operates in the single-use bioprocessing market through the life science solutions business segment. To further increase its share in the single-use bioprocessing market, the company focuses on growth strategies such as acquisitions and expansion. From 2019 to 2021, the company expanded its business in the US. The company also made investments worth ~USD 650 million from 2019 to 2021 to enhance their single-use bioprocessing capabilities and increase their market share.

The single-use media bags and containers segment currently dominates the market, driven by their widespread use across biomanufacturing processes. However, demand is strong across all application areas including filtration, storage, cell culture, mixing, and purification.

As biopharmaceutical production continues ramping up globally, the future looks extremely bright for flexible, cost-effective single-use bioprocessing solutions to unlock new manufacturing efficiencies and accelerate delivery of life-saving treatments.

Recent Developments of Single Use Bioprocessing Industry:

• In March 2020, Danaher acquired the Biopharma business from General Electric Company’s Life Sciences division. The business is called Cytiva, and is a standalone operating company within Danaher’s Life Sciences segment.
• In September 2020, Thermo Fisher Scientific invested more than USD 475 million in new capabilities at its St. Louis site to expand biologics development and manufacturing, cell and gene therapy capabilities, and drug product development capabilities.